Skip to content
2000
Volume 18, Issue 5
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Neglected diseases comprise a number of infectious diseases historically endemic to low- and middle-income countries, though recently they have spread to high-income countries due to human migrations. In the past, pharmaceutical companies have shown hesitant to invest in these health conditions, due to the limited return on investment. As a result, the role of the academic sector and not-for-profit organizations in the discovery of new drugs for neglected diseases has been particularly relevant. Here, we review recent applications of modern drug discovery technologies in the field of neglected diseases, including high-throughput screening, in silico screening and computer-aided drug design. The suitability and perspectives of each approach are discussed depending on the context, along with the technology and translational gaps influencing them.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026618666180509151146
2018-02-01
2025-07-11
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026618666180509151146
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test